Related Experiment Video
Updated: May 16, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine
Ian Major1, Peter Boyd, Maggie Kilbourne-Brook
1School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Background:
There is considerable interest in developing new multipurpose prevention technologies to address women's reproductive health needs. This study describes an innovative barrier contraceptive device--based on the SILCS diaphragm--that also provides long-term controlled release of the lead candidate anti-HIV microbicide dapivirine.
Study Design:
Diaphragm devices comprising various dapivirine-loaded polymer spring cores overmolded with a nonmedicated silicone elastomer sheath were fabricated by injection molding processes. In vitro release testing, thermal analysis and mechanical characterization were performed on the devices.
Results:
A diaphragm device containing a polyoxymethylene spring core loaded with 10% w/w dapivirine provided continuous and controlled release of dapivirine over a 6-month period, with a mean in vitro daily release rate of 174 mcg/day. The mechanical properties of the new diaphragm were closely matched to the SILCS diaphragm.
Conclusions:
The study demonstrates proof of concept for a dapivirine-releasing diaphragm with daily release quantities potentially capable of preventing HIV transmission. In discontinuous clinical use, release of dapivirine may be readily extended over 1 or more years.
Related Concept Videos
Intrauterine Drug Delivery Systems
Modified-Release Drug Delivery Systems: Rate-Programmed I
Modified-Release Drug Delivery Systems: Rate-Programmed II
Oral Drug Delivery Systems: Continuous-Release Systems
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Transdermal Drug Delivery Systems

